News Orexo AB

Equities

ORX

SE0000736415

Delayed Nasdaq Stockholm Other stock markets 03:33:42 2024-04-23 am EDT			5-day change	1st Jan Change
15.74 ^SEK	-0.25%		-6.97%	+1.81%

Apr. 17	Orexo Expands, Extends US Patent for Nasal Anaphylaxis Treatment	MT
Apr. 17	Orexo Extends Patent Protection for Its Nasal Epinephrine Powder Product OX640 in the US	CI

Summary

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Orexo Expands, Extends US Patent for Nasal Anaphylaxis Treatment	Apr. 17	MT
Orexo extends patent protection for its nasal epinephrine powder product OX640 in the US	Apr. 17	AQ
Orexo Extends Patent Protection for Its Nasal Epinephrine Powder Product OX640 in the US	Apr. 17	CI
Sweden's Orexo Set for Early Redemption of Bonds Due 2025	Apr. 02	MT
Orexo announces that the condition for early redemption of its existing bonds has been fulfilled	Apr. 02	AQ
Orexo publishes the Annual and Sustainability Report for 2023	Mar. 28	AQ
Orexo AB Announces Board Resignations	Mar. 22	CI
Correction: Notice of Annual General Meeting of Orexo	Mar. 15	AQ
Notice of Annual General Meeting of Orexo	Mar. 15	AQ
Orexo Issues SEK500 Million Social Bonds, Closes Tender Offer	Mar. 14	MT
Orexo Issues Senior Secured Callable Floating Rate Social Bonds of SEK 500 Million and Announces Results of the Tender Offer for Its Existing Bonds	Mar. 13	CI
Orexo successfully issues senior secured callable floating rate social bonds of SEK 500 m and announces results of the tender offer for its existing bonds	Mar. 13	AQ
Orexo Plans SEK500 Million New Social Bond Issuance, Tender Offer	Mar. 08	MT
Orexo contemplates issuance of senior secured callable floating rate social bonds and announces a conditional tender offer for its existing bonds	Mar. 08	AQ
Orexo strengthens its sustainability work by establishing a social financing framework	Mar. 08	AQ
Orexo, Swedish Orphan Biovitrum to Further Explore AmorphOX Combination	Feb. 12	MT
Orexo and Sobi agree to advance feasibility study with AmorphOX	Feb. 12	AQ
Orexo AB (Publ.) and Swedish Orphan Biovitrum AB (publ.) Agrees to Advance Feasibility Study with Amorphox	Feb. 12	CI
Transcript : Orexo AB, 2023 Earnings Call, Feb 08, 2024	Feb. 08
Orexo Interim Report Q4 2023, incl. Full Year Report	Feb. 08	AQ

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

+39.41% on our US portfolio vs. 25.67% on the S&P 500 net Total Return

Replicate our performance

fermer